In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
0-9 years 10-17 years 18-26 years
Genetically Modified T cells
Condition: Acute Lymphocytic Leukemia, Lymphoma
The purpose of this study is to test the safety of giving the patient special cells from a donor called “Modified T-cells”. The goal is to find a safe dose of modified T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT. The investigators also want to find out what effects these T-cells have on the patient and the disease.